Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials (Q37696496)

22 August 2017

Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials (English)

1 reference

22 August 2017

phase II clinical trial

0 references

type 2 diabetes

0 references

author name string

Katherine R Tuttle

1

1 reference

22 August 2017

T Dwight McKinney

2

1 reference

22 August 2017

Jaime A Davidson

3

1 reference

22 August 2017

Greg Anglin

4

1 reference

22 August 2017

Kristine D Harper

5

1 reference

22 August 2017

Fady T Botros

6

1 reference

22 August 2017

21 October 2016

1 reference

Diabetes, Obesity and Metabolism

22 August 2017

1 reference

22 August 2017

19

1 reference

22 August 2017

3

1 reference

22 August 2017

436-441

1 reference

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5347883

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5347883

Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5347883

Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5347883

Frequency of hypoglycemia and its significance in chronic kidney disease.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5347883

A new equation to estimate glomerular filtration rate

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5347883

Effect of renal impairment on the pharmacokinetics of exenatide

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5347883

Progression of diabetic nephropathy

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5347883

Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5347883

Diabetic kidney disease: a report from an ADA Consensus Conference.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5347883

The potential for renoprotection with incretin-based drugs

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5347883

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5347883

Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5347883

Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5347883

Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5347883

A study of the natural history of diabetic kidney disease (DKD).

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5347883

Mild renal impairment and the efficacy and safety of liraglutide

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5347883

Regulation of Na /H exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5347883

Exenatide-associated ischemic renal failure.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5347883

Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5347883

KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5347883

Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5347883

Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5347883

Renal effects of glucagon-like peptide in rats

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5347883

Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers

2 October 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111/DOM.12816

The use of eGFR and ACR to predict decline in renal function in people with diabetes

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111/DOM.12816

Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells

21 January 2018

1 reference

12 December 2020

The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients

1 reference

12 December 2020

Liraglutide-induced acute kidney injury

1 reference

12 December 2020

The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential

1 reference

12 December 2020

Observational study of kidney function and albuminuria in patients with type 2 diabetes treated with exenatide BID versus insulin glargine

1 reference

12 December 2020

Effects of exenatide on kidney function, adverse events, and clinical end points of kidney disease in type 2 diabetes

1 reference

12 December 2020

Identifiers

DOI

10.1111/DOM.12816

1 reference

22 August 2017

1 reference

22 August 2017

PubMed publication ID

27766728

1 reference